Cargando…

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Maggi, Fabrizio, McConnell, Scott, Casadevall, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846359/ https://www.ncbi.nlm.nih.gov/pubmed/35164530 http://dx.doi.org/10.2217/fmb-2021-0286

Ejemplares similares

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
por: Saunders, Nell, et al.
Publicado: (2022)

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
por: Focosi, Daniele, et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
por: Baj, Andreina, et al.
Publicado: (2021)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
por: Nyberg, Tommy, et al.
Publicado: (2022)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy
por: Focosi, Daniele, et al.
Publicado: (2023)

A CLUSTER OF SARS‐COV‐2 DELTA VARIANT OF CONCERN ADDITIONALLY HARBORING F490S, NORTHERN LOMBARDY, ITALY
por: Novazzi, Federica, et al.
Publicado: (2022)

Molecular Epidemiology of AY.28 and AY.104 Delta Sub-lineages in Sri Lanka
por: Ranasinghe, Diyanath, et al.
Publicado: (2022)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 evolution among patients with immunosuppression in a nosocomial cluster of a Japanese medical center during the Delta (AY.29 sublineage) surge
por: Hosaka, Yoshie, et al.
Publicado: (2023)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
por: Focosi, Daniele, et al.
Publicado: (2022)

Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico
por: Taboada, Blanca, et al.
Publicado: (2022)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 Delta Variant (AY.3) in the Feces of a Domestic Cat
por: Lenz, Olivia C., et al.
Publicado: (2022)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Ay mi!
por: Guillaume, de Machaut, ca. 1300-1377
Publicado: (1997)

SARS-CoV-2 Delta AY.1 Variant Cluster in an Accommodation Facility for COVID-19: Cluster Report
por: Ohishi, Takayuki, et al.
Publicado: (2022)

Early introduction, dispersal and evolution of Delta SARS-CoV-2 in Southern Brazil, late predominance of AY.99.2 and AY.101 related lineages
por: Gularte, Juliana Schons, et al.
Publicado: (2022)

Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63
por: Moen, Line Victoria, et al.
Publicado: (2022)

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Near-Complete Genome of SARS-CoV-2 Delta (AY.3) Variant Identified in a Dog in Kansas, USA
por: Doerksen, Tyler, et al.
Publicado: (2021)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Rapid emergence of omicron sublineages expressing spike protein R346T
por: Groenheit, Ramona, et al.
Publicado: (2022)

¡Ay cosita! : sones campesinos.
Publicado: (2001)

¡Ay, Nicaragua, Nicaraguita!
Publicado: (1993)

Ay, Nicaragua, Nicaragüita! /
por: Roffiel, Rosa María
Publicado: (1986)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Baj, Andreina, et al.
Publicado: (2021)

Cross-Border Transmissions of the Delta Substrain AY.29 During Tokyo Olympic and Paralympic Games
por: Koyama, Takahiko, et al.
Publicado: (2022)

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
por: Akache, Bassel, et al.
Publicado: (2022)

The Delta variant wave in Tunisia: Genetic diversity, spatio-temporal distribution and evidence of the spread of a divergent AY.122 sub-lineage
por: Haddad-Boubaker, Sondes, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ef5a1cbejrauua6k7fcmcgd6bf